Franck Morschhauser

End-of-induction circulating tumor DNA outperforms conventional cellular MRD for predicting early progression in follicular lymphoma: an ancillary study of the RELEVANCE randomized trial

In this ancillary study of the RELEVANCE phase III trial (NCT01650701), we performed the first direct intra-patient comparison of circulating tumor DNA (ctDNA)-based versus cellular t( BCL2 / JH ) translocation-based MRD at end of induction (EOI) in 278 patients with advanced FL,...